Last reviewed · How we verify

Pentoxifylline and Tocopherol

Hospital Vall d'Hebron · FDA-approved active Small molecule Quality 5/100

Pentoxifylline and Tocopherol is a Small molecule drug developed by Hospital Vall d'Hebron. It is currently FDA-approved. Also known as: PENTO.

At a glance

Generic namePentoxifylline and Tocopherol
Also known asPENTO
SponsorHospital Vall d'Hebron
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Pentoxifylline and Tocopherol

What is Pentoxifylline and Tocopherol?

Pentoxifylline and Tocopherol is a Small molecule drug developed by Hospital Vall d'Hebron.

Who makes Pentoxifylline and Tocopherol?

Pentoxifylline and Tocopherol is developed and marketed by Hospital Vall d'Hebron (see full Hospital Vall d'Hebron pipeline at /company/hospital-vall-d-hebron).

Is Pentoxifylline and Tocopherol also known as anything else?

Pentoxifylline and Tocopherol is also known as PENTO.

What development phase is Pentoxifylline and Tocopherol in?

Pentoxifylline and Tocopherol is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing